alcohol-related disorders, 490–503
caffeine-related disorders, 503–509
cannabis-related disorders, 509–519
diagnoses associated with substance class, 
482
drug classes in, 481
hallucinogen-related disorders, 520–533
inhalant-related disorders, 533–540
opioid-related disorders, 540–550
other (or unknown) substance–related 
disorders, 577–585sedative-, hypnotic- or anxiolytic-related 
disorders, 550–560
stimulant-related disorders, 561–570
substance-induced disorders, 481, 485–490
substance use disorders, 481, 483–485, 
490–585
tobacco-related disorders, 571–577
Substance use disorders, 481, 483–485
alcohol use disorder, 490–497
caffeine use disorder, 792–795
cannabis use disorder, 509–516
features of, 483–484
inhalant use disorder, 533–538
opioid use disorder, 541–546
other hallucinogen use disorder, 523–527
other (or unknown) substance use disorder, 
577–580
phencyclidine use disorder, 520–523
recording procedures for, 485
sedative, hypnotic, or anxiolytic use disorder, 
550–556
severity and specifiers for, 484
stimulant use disorder, 561–567
tobacco use disorder, 571–574
tolerance and withdrawal in, 484
Substance withdrawal delirium, 597, 598–599
Suicidal behavior disorder, 801–803
comorbidity with, 803
culture-related diagnostic issues in, 802